AIM: Left ventricular (LV) dysfunction during and after hospitalization for ST-segment elevation myocardial infarction (STEMI) is associated with increased mortality. Whether baseline LV dysfunction impacts STEMI outcomes is not well studied. Furthermore, whether bivalirudin and paclitaxel-eluting stents (PES) are beneficial in patients with LV dysfunction is unknown. We studied the impact of left ventricular ejection fraction (LVEF) on outcomes of patients with STEMI in the HORIZONS-AMI trial. METHODS:LVEF was determined in 2648 (73.5%) of 3602 enrolled STEMI patients, who were divided into three groups according to LV function: (1) severely impaired (LVEF <40%); (2) moderately impaired (LVEF 40-50%); and (3) normal (LVEF ≥50%). RESULTS: Compared to patients with normal LV function, those with severely impaired LVEF had higher 1-year rates of net adverse clinical events (27.1 vs. 14.2%, p<0.0001), major adverse cardiovascular events (20.7 vs. 9.5%, p<0.0001), cardiac death (10.6 vs. 1.2%, p<0.0001), and non-coronary artery bypass graft major bleeding (12.5 vs. 6.6%, p=0.001), differences which persisted after adjustment for baseline characteristics. Among patients with LVEF <40%, treatment with bivalirudin compared to heparin+GPIIb/IIIa inhibitors resulted in reduced 1-year mortality (5.8 vs. 18.3%, p=0.007). Patients with LVEF <40% receiving PES rather than bare metal stents had lower rates of 1-year ischaemia-driven target lesion revascularization (2.9 vs. 12.6%, p=0.02) and reinfarction (4.5 vs. 14.7%, p=0.03). CONCLUSIONS: Among patients with STEMI undergoing primary percutaneous coronary intervention, adverse events are markedly increased in those with LVEF <40% during the index revascularization procedure. Nevertheless, these high-risk patients experience substantial clinical benefits from bivalirudin and PES.
RCT Entities:
AIM: Left ventricular (LV) dysfunction during and after hospitalization for ST-segment elevation myocardial infarction (STEMI) is associated with increased mortality. Whether baseline LV dysfunction impacts STEMI outcomes is not well studied. Furthermore, whether bivalirudin and paclitaxel-eluting stents (PES) are beneficial in patients with LV dysfunction is unknown. We studied the impact of left ventricular ejection fraction (LVEF) on outcomes of patients with STEMI in the HORIZONS-AMI trial. METHODS: LVEF was determined in 2648 (73.5%) of 3602 enrolled STEMI patients, who were divided into three groups according to LV function: (1) severely impaired (LVEF <40%); (2) moderately impaired (LVEF 40-50%); and (3) normal (LVEF ≥50%). RESULTS: Compared to patients with normal LV function, those with severely impaired LVEF had higher 1-year rates of net adverse clinical events (27.1 vs. 14.2%, p<0.0001), major adverse cardiovascular events (20.7 vs. 9.5%, p<0.0001), cardiac death (10.6 vs. 1.2%, p<0.0001), and non-coronary artery bypass graft major bleeding (12.5 vs. 6.6%, p=0.001), differences which persisted after adjustment for baseline characteristics. Among patients with LVEF <40%, treatment with bivalirudin compared to heparin+GPIIb/IIIa inhibitors resulted in reduced 1-year mortality (5.8 vs. 18.3%, p=0.007). Patients with LVEF <40% receiving PES rather than bare metal stents had lower rates of 1-year ischaemia-driven target lesion revascularization (2.9 vs. 12.6%, p=0.02) and reinfarction (4.5 vs. 14.7%, p=0.03). CONCLUSIONS: Among patients with STEMI undergoing primary percutaneous coronary intervention, adverse events are markedly increased in those with LVEF <40% during the index revascularization procedure. Nevertheless, these high-risk patients experience substantial clinical benefits from bivalirudin and PES.
Entities:
Keywords:
Bivalirudin; ST-elevation myocardial infarction; drug-eluting stent; left ventricular dysfunction
Authors: Jacob E Møller; Kenneth Egstrup; Lars Køber; Steen H Poulsen; Ole Nyvad; Christian Torp-Pedersen Journal: Am Heart J Date: 2003-01 Impact factor: 4.749
Authors: Amir Halkin; Mandeep Singh; Eugenia Nikolsky; Cindy L Grines; James E Tcheng; Eulogio Garcia; David A Cox; Mark Turco; Thomas D Stuckey; Yingo Na; Alexandra J Lansky; Bernard J Gersh; William W O'Neill; Roxana Mehran; Gregg W Stone Journal: J Am Coll Cardiol Date: 2005-05-03 Impact factor: 24.094
Authors: E Loh; M S Sutton; C C Wun; J L Rouleau; G C Flaker; S S Gottlieb; G A Lamas; L A Moyé; S Z Goldhaber; M A Pfeffer Journal: N Engl J Med Date: 1997-01-23 Impact factor: 91.245
Authors: Raisuke Iijima; Gjin Ndrepepa; Julinda Mehilli; Robert A Byrne; Stefanie Schulz; Franz-Josef Neumann; Gert Richardt; Peter B Berger; Albert Schömig; Adnan Kastrati Journal: Eur Heart J Date: 2009-01-15 Impact factor: 29.983
Authors: Giulio Guagliumi; Gregg W Stone; David A Cox; Thomas Stuckey; James E Tcheng; Mark Turco; Giuseppe Musumeci; John J Griffin; Alexandra J Lansky; Roxana Mehran; Cindy L Grines; Eulogio Garcia Journal: Circulation Date: 2004-09-07 Impact factor: 29.690
Authors: Elliott M. Antman; Daniel T. Anbe; Paul Wayne Armstrong; Eric R. Bates; Lee A. Green; Mary Hand; Judith S. Hochman; Harlan M. Krumholz; Frederick G. Kushner; Gervasio A. Lamas; Charles J. Mullany; Joseph P. Ornato; David L. Pearle; Michael A. Sloan; Sidney C. Smith; Joseph S. Alpert; Jeffrey L. Anderson; David P. Faxon; Valentin Fuster; Raymond J. Gibbons; Gabriel Gregoratos; Jonathan L. Halperin; Loren F. Hiratzka; Sharon Ann Hunt; Alice K. Jacobs; Joseph P. Ornato Journal: J Am Coll Cardiol Date: 2004-08-04 Impact factor: 24.094
Authors: Roxana Mehran; Alexandra J Lansky; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; S Chiu Wong; Eugenia Nikolsky; Louise Gambone; Lynn Vandertie; Helen Parise; George D Dangas; Gregg W Stone Journal: Lancet Date: 2009-08-28 Impact factor: 79.321
Authors: Steven V Manoukian; Frederick Feit; Roxana Mehran; Michele D Voeltz; Ramin Ebrahimi; Martial Hamon; George D Dangas; A Michael Lincoff; Harvey D White; Jeffrey W Moses; Spencer B King; E Magnus Ohman; Gregg W Stone Journal: J Am Coll Cardiol Date: 2007-03-09 Impact factor: 24.094
Authors: M St John Sutton; M A Pfeffer; T Plappert; J L Rouleau; L A Moyé; G R Dagenais; G A Lamas; M Klein; B Sussex; S Goldman Journal: Circulation Date: 1994-01 Impact factor: 29.690
Authors: Jose P S Henriques; Felix Zijlstra; Menko-Jan de Boer; Arnoud W J van 't Hof; A T Marcel Gosselink; Jan-Henk E Dambrink; Harry Suryapranata; Jan C A Hoorntje Journal: Eur J Heart Fail Date: 2003-06 Impact factor: 15.534
Authors: Wanda Y Wu; David W Biery; Avinainder Singh; Sanjay Divakaran; Adam N Berman; Gloria Ayuba; Ersilia M DeFilippis; Khurram Nasir; James L Januzzi; Marcelo F Di Carli; Deepak L Bhatt; Ron Blankstein Journal: J Am Coll Cardiol Date: 2020-06-09 Impact factor: 24.094
Authors: Nicola Galea; Gian Marco Dacquino; Rosa Maria Ammendola; Simona Coco; Luciano Agati; Laura De Luca; Iacopo Carbone; Francesco Fedele; Carlo Catalano; Marco Francone Journal: Eur Radiol Date: 2018-12-14 Impact factor: 5.315
Authors: Martin Reindl; Christina Tiller; Magdalena Holzknecht; Ivan Lechner; Dorothea Eisner; Laura Riepl; Mathias Pamminger; Benjamin Henninger; Agnes Mayr; Johannes P Schwaiger; Gert Klug; Axel Bauer; Bernhard Metzler; Sebastian J Reinstadler Journal: Clin Res Cardiol Date: 2020-04-15 Impact factor: 5.460
Authors: Magdy Abdel Hamid; Sameh W G Bakhoum; Yasser Sharaf; Dina Sabry; Ahmed T El-Gengehe; Ahmed Abdel-Latif Journal: J Interv Cardiol Date: 2016-02 Impact factor: 2.279
Authors: Marjo Okkonen; Aki S Havulinna; Olavi Ukkola; Heikki Huikuri; Arto Pietilä; Heli Koukkunen; Seppo Lehto; Juha Mustonen; Matti Ketonen; Juhani Airaksinen; Y Antero Kesäniemi; Veikko Salomaa Journal: Ann Med Date: 2021-12 Impact factor: 4.709
Authors: Marie Dam Lauridsen; Henrik Gammelager; Morten Schmidt; Thomas Bøjer Rasmussen; Richard E Shaw; Hans Erik Bøtker; Henrik Toft Sørensen; Christian Fynbo Christiansen Journal: Crit Care Date: 2015-12-30 Impact factor: 9.097